Apelin and the gut microbiome: Potential interaction in human MASLD
Digestive and Liver Disease · 2024-06 · 56 (6) · 932-940
DOI: 10.1016/j.dld.2023.11.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024-06. Verfasst von Maria Effenberger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Apelin, Gastrointestinal Microbiome, Carcinoma, Hepatocellular, Liver Cirrhosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with increasing numbers worldwide. Adipokines like apelin (APLN) can act as key players in the complex pathophysiology of MASLD. AIMS: Investigating the role of APLN in MASLD. METHODS: Fecal and blood samples were collected in a MASLD cohort and healthy controls (HC). MASLD patients with liver fibrosis and MASLD-associated hepatocellular carcinoma (HCC) were included into the study. Systemic concentration of Apelin, Apelin receptor (APLNR) and circulating cytokines were measured in serum samples. RESULTS: Apelin concentration correlated with the Fib-4 score and was elevated in MASLD patients (mild fibrosis, mF (Fib-4 3.25)) as well as in MASLD-associated HCC patients compared to HC. In accordance APLNR and circulating cytokines were also elevated in mF and sF. In contrast apelin levels were negatively associated with liver survival at three and five years. Changes in taxa composition at phylum level showed an increase of Enterobactericae, Prevotellaceae and Lactobacillaceae in patients with sF compared to mF. We could also observe an association between apelin concentrations and bacterial lineages (phyla). CONCLUSIONS: Circulating apelin is associated with liver fibrosis and HCC. In addition, there might exist an interaction between systemic apelin and the gut microbiome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: christoph.grander@i-med.ac.at.
- Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria; Centre for Microbiology and Environmental Systems Science, Department of Microbiology and Ecosystem Science, D…
Zitieren
APA
Effenberger, M., Grander, C., Hausmann, B., Enrich, B., Pjevac, P., Zoller, H., & Tilg, H. (2024). Apelin and the gut microbiome: Potential interaction in human MASLD. Digestive and Liver Disease, 56(6), 932-940. https://doi.org/10.1016/j.dld.2023.11.023
Vancouver
Effenberger M, Grander C, Hausmann B, Enrich B, Pjevac P, Zoller H, et al. Apelin and the gut microbiome: Potential interaction in human MASLD. Digestive and Liver Disease. 2024;56(6):932-940. doi:10.1016/j.dld.2023.11.023
BibTeX
@article{Effenberger2024,
author = {Effenberger, Maria and Grander, Christoph and Hausmann, Bela and Enrich, Barbara and Pjevac, Petra and Zoller, Heinz and Tilg, Herbert},
title = {Apelin and the gut microbiome: Potential interaction in human MASLD},
journal = {Digestive and Liver Disease},
year = {2024},
volume = {56},
number = {6},
pages = {932--940},
doi = {10.1016/j.dld.2023.11.023}
}
EUVIMED